Hui-ming Lin
Research Officer
Clinical Prostate Cancer Research
Garvan Institute of Medical Research
Australia
Biography
Hui-Ming completed her PhD degree at the University of Auckland in 2010. Her PhD thesis was about the metabolomic analysis of the interleukin-10 knockout mouse model of inflammatory bowel disease. Prior to her PhD studies, she was an Assistant Research Fellow in the Cancer Genetics Laboratory, University of Otago, New Zealand, from 2004-2006. Her current research at the Garvan Institute focuses on identifying therapeutic response biomarkers and elucidating the mechanisms of chemotherapy resistance in metastatic prostate cancer.
Research Interest
biomarker discovery; predicting and improving therapeutic response in prostate cancer; role of microRNAs in therapeutic response
Publications
-
Lin H-M, Barnett MP, Roy NC, Joyce NI, Zhu S, Armstrong K, Helsby NA, Ferguson LR, Rowan DD. Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn’s disease. J Proteome Res. 2010;9(4):1965-1975
-
Mahon KL, Lin H-M, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, Horvath LG. Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer. 2015; 112 (8):1340-1348
-
Lin H-M, Mahon KL, Spielman C, Gurney H, Mallesara G, Stockler MR, Bastick P, Briscoe K, Marx G, Swarbrick A, Horvath LG. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. Br J Cancer. 2017; 116 (8):1002-1011
